{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:09:39Z","timestamp":1784196579626,"version":"3.55.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-05016-y","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:33:59Z","timestamp":1781152439000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clazosentan in aneurysmal subarachnoid hemorrhage: an updated systematic review and meta-analysis of efficacy and safety"],"prefix":"10.1186","volume":"26","author":[{"given":"Abdulelah Mohammed","family":"Alsakti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Hassan Al","family":"Ghazwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman Khalid","family":"AlOtaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Abdullah","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layan Ali","family":"Aldeaiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz Bijad","family":"Binshmilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naif Mohammed M.","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehaf Essa","family":"Alsharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad Mohammed","family":"Aldehaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil Anas","family":"Alhindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah Abdullah","family":"Alodhaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aalaa","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Altamimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"2","key":"5016_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4274\/balkanmedj.galenos.2023","volume":"40","author":"KR Ran","year":"2023","unstructured":"Ran KR, Wang AC, Nair SK, Ak\u00e7a O, Xu R. Acute Multidisciplinary Management of Aneurysmal Subarachnoid Hemorrhage (aSAH). Balkan Med J. 2023;40(2):74\u201381. https:\/\/doi.org\/10.4274\/balkanmedj.galenos.2023.2023-1-100. PubMed PMID: 36883719.","journal-title":"Balkan Med J"},{"issue":"1","key":"5016_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12028-018-0650-5","volume":"32","author":"F Oka","year":"2019","unstructured":"Oka F, Chung DY, Suzuki M, Ayata C. Delayed Cerebral Ischemia After Subarachnoid Hemorrhage: Experimental-Clinical Disconnect and the Unmet Need. Neurocritical Care 2019. 2019;32(1):1. https:\/\/doi.org\/10.1007\/s12028-018-0650-5 . PubMed PMID: 30671784.","journal-title":"Neurocritical Care 2019"},{"issue":"1","key":"5016_CR3","doi-asserted-by":"publisher","first-page":"506584","DOI":"10.1155\/2013\/506584","volume":"2013","author":"KR Carr","year":"2013","unstructured":"Carr KR, Zuckerman SL, Mocco J, Inflammation. Cerebral Vasospasm, and Evolving Theories of Delayed Cerebral Ischemia. Neurol Res Int. 2013;2013(1):506584. https:\/\/doi.org\/10.1155\/2013\/506584.","journal-title":"Neurol Res Int"},{"issue":"6","key":"5016_CR4","doi-asserted-by":"publisher","first-page":"843","DOI":"10.2174\/1567201813666160808100937","volume":"14","author":"S Hasegawa","year":"2016","unstructured":"Hasegawa S, Hasegawa Y, Miura M. Current Therapeutic Drugs Against Cerebral Vasospasm after Subarachnoid Hemorrhage: A Comprehensive Review of Basic and Clinical Studies. Curr Drug Deliv. 2016;14(6):843\u201352. https:\/\/doi.org\/10.2174\/1567201813666160808100937.\u00a0PubMed PMID: 27501717.","journal-title":"Curr Drug Deliv"},{"issue":"1","key":"5016_CR5","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s11940-013-0278-x","volume":"16","author":"S Izzy","year":"2014","unstructured":"Izzy S, Muehlschlegel S. Cerebral vasospasm after aneurysmal subarachnoid hemorrhage and traumatic brain injury. Curr Treat Options Neurol. 2014;16(1):278. https:\/\/doi.org\/10.1007\/s11940-013-0278-x.","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"5016_CR6","doi-asserted-by":"publisher","first-page":"462491","DOI":"10.1155\/2013\/462491","volume":"2013","author":"P Adamczyk","year":"2013","unstructured":"Adamczyk P, He S, Amar AP, Mack WJ. Medical Management of Cerebral Vasospasm following Aneurysmal Subarachnoid Hemorrhage: A Review of Current and Emerging Therapeutic Interventions. Neurol Res Int. 2013;2013(1):462491. https:\/\/doi.org\/10.1155\/2013\/462491.","journal-title":"Neurol Res Int"},{"issue":"1","key":"5016_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s12028-023-01847-6","volume":"40","author":"MM Caylor","year":"2024","unstructured":"Caylor MM, Macdonald RL. Pharmacological Prevention of Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage. Neurocrit Care. 2024;40(1):159\u201369. https:\/\/doi.org\/10.1007\/s12028-023-01847-6 . PubMed PMID: 37740138.","journal-title":"Neurocrit Care"},{"issue":"1","key":"5016_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.wneu.2015","volume":"84","author":"AMH Young","year":"2015","unstructured":"Young AMH, Karri SK, Helmy A, Budohoski KP, Kirollos RW, Bulters DO, et al. Pharmacologic Management of Subarachnoid Hemorrhage. World Neurosurg. 2015;84(1):28\u201335. https:\/\/doi.org\/10.1016\/j.wneu.2015.02.004.\u00a0 PubMed PMID: 25701766.","journal-title":"World Neurosurg"},{"key":"5016_CR9","doi-asserted-by":"publisher","first-page":"628956","DOI":"10.3389\/fphar.2020.628956","volume":"11","author":"PE Juif","year":"2021","unstructured":"Juif PE, Dingemanse J, Ufer M. Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm. Front Pharmacol. 2021;11:628956. https:\/\/doi.org\/10.3389\/fphar.2020.628956.","journal-title":"Front Pharmacol"},{"key":"5016_CR10","doi-asserted-by":"publisher","unstructured":"Lee A, Clazosentan. First Approval. Drugs 2022 82:6. 2022;82(6):697\u2013702. https:\/\/doi.org\/10.1007\/s40265-022-01708-0. PubMed PMID: 35362854.","DOI":"10.1007\/s40265-022-01708-0"},{"issue":"6","key":"5016_CR11","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.3171\/2022.2","volume":"137","author":"H Endo","year":"2022","unstructured":"Endo H, Hagihara Y, Kimura N, Takizawa K, Niizuma K, Togo O, et al. Effects of clazosentan on cerebral vasospasm\u2013related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients. J Neurosurg. 2022;137(6):1707\u201317. https:\/\/doi.org\/10.3171\/2022.2.JNS212914. PubMed PMID: 35364589.","journal-title":"J Neurosurg"},{"issue":"1","key":"5016_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2176\/jns-nmc.2024-0204","volume":"65","author":"S Kajiwara","year":"2025","unstructured":"Kajiwara S, Kawano T, Hasegawa Y, Nakamura Y, Sakata K, Kikuchi J, et al. Impact of Clazosentan on Vasospasm Reduction and Functional Recovery after Aneurysmal Subarachnoid Hemorrhage. Neurol Med Chir (Tokyo). 2025;65(1):29\u201336. https:\/\/doi.org\/10.2176\/jns-nmc.2024-0204 . PubMed PMID: 39581616.","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"7","key":"5016_CR13","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S1474-4422","volume":"10","author":"RL Macdonald","year":"2011","unstructured":"Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: A randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol. 2011;10(7):618\u201325. https:\/\/doi.org\/10.1016\/S1474-4422(11)70108-9. PubMed PMID: 21640651.","journal-title":"Lancet Neurol"},{"issue":"2","key":"5016_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/J.HEST.2023.11.006","volume":"5","author":"H Maeda","year":"2024","unstructured":"Maeda H, Izumo T, Okamura K, Yamaguchi S, Morofuji Y, Matsuo T. Evolving approaches in the management of patients with subarachnoid hemorrhage from 2002 to 2022: The impact of clazosentan and treatment modalities on outcomes. Brain Hemorrhages. 2024;5(2):55\u201361. https:\/\/doi.org\/10.1016\/J.HEST.2023.11.006.","journal-title":"Brain Hemorrhages"},{"key":"5016_CR15","doi-asserted-by":"publisher","unstructured":"Raja S, Raja A, Shuja MH, Ali A. Clazosentan\u2019s dual edge in managing vasospasm following aneurysmal subarachnoid hemorrhage: an updated systematic review, meta-analysis, and meta-regression of clinical outcomes and safety profiles. Neurosurg Rev. 2025;48(1). https:\/\/doi.org\/10.1007\/S10143-024-03173-7. PubMed PMID: 39753744.","DOI":"10.1007\/S10143-024-03173-7"},{"key":"5016_CR16","doi-asserted-by":"publisher","unstructured":"Abunada S, Ashraf T, Kumar D, Moryani HA, Rai P, Abbasi S, et al. Clazosentan for cerebral vasospasm prevention in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. BMC Neurol. 2025;25(1). https:\/\/doi.org\/10.1186\/s12883-025-04429-5. PubMed PMID: 41053596.","DOI":"10.1186\/s12883-025-04429-5"},{"key":"5016_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jocn.2024.06","volume":"126","author":"MM Al-Salihi","year":"2024","unstructured":"Al-Salihi MM, Saha R, Abd Elazim A, Helal A, Sabah Al-Jebur M, Al-Salihi Y, et al. The effectiveness and safety of clazosentan in treating aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis. J Clin Neurosci. 2024;126:173\u201381. https:\/\/doi.org\/10.1016\/j.jocn.2024.06.019. PubMed PMID: 38924824.","journal-title":"J Clin Neurosci"},{"key":"5016_CR18","doi-asserted-by":"publisher","unstructured":"Kondo H, Ishii D, Kuwabara M, Hara T, Kurisu K, Sumida M, et al. Multicenter Validation of a Unified Evidence-Based Treatment Protocol Focusing on Clazosentan for Managing Subarachnoid Hemorrhage. J Clin Med. 2025;14(10). https:\/\/doi.org\/10.3390\/jcm14103423 . PubMed PMID: 40429418.","DOI":"10.3390\/jcm14103423"},{"key":"5016_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X251399068","author":"H Sakata","year":"2025","unstructured":"Sakata H, Uchida H, Kanoke A, Omodaka S, Tashiro R, Sato Y, et al. Stratified assessment of clazosentan efficacy following subarachnoid hemorrhage: A multi-center cohort study. J Cereb Blood Flow Metab. 2025. https:\/\/doi.org\/10.1177\/0271678X251399068 . PubMed PMID: 41272408.","journal-title":"J Cereb Blood Flow Metab"},{"key":"5016_CR20","doi-asserted-by":"publisher","unstructured":"Ogawa S, Koizumi S, Umekawa M, Fujitani S, Ono H, Miyawaki S et al. Quantitative evaluation of the vasodilatory effect of clazosentan in preventing cerebral vasospasm after subarachnoid hemorrhage. Interv Neuroradiol. 2025. https:\/\/doi.org\/10.1177\/15910199251362730. PubMed PMID: 40767159.","DOI":"10.1177\/15910199251362730"},{"issue":"3","key":"5016_CR21","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3171\/2025.1","volume":"143","author":"S Muraoka","year":"2025","unstructured":"Muraoka S, Izumi T, Nishida K, Chr\u00e9tien B, Ishii K, Takeuchi I, et al. RECOVER study: a multicenter retrospective cohort study and comparison of the efficacy and safety of clazosentan and fasudil in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg. 2025;143(3):624\u201333. https:\/\/doi.org\/10.3171\/2025.1.JNS242509. PubMed PMID: 40378483.","journal-title":"J Neurosurg"},{"key":"5016_CR22","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int J Surg. 2021;88. https:\/\/doi.org\/10.1016\/J.IJSU.2021.105906. PubMed PMID: 33789826.","DOI":"10.1016\/J.IJSU.2021.105906"},{"key":"5016_CR23","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366. https:\/\/doi.org\/10.1136\/BMJ.L4898. PubMed PMID: 31462531.","DOI":"10.1136\/BMJ.L4898"},{"key":"5016_CR24","doi-asserted-by":"publisher","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355. https:\/\/doi.org\/10.1136\/BMJ.I4919. PubMed PMID: 27733354.","DOI":"10.1136\/BMJ.I4919"},{"key":"5016_CR25","unstructured":"Chapter 23. Including variants on randomized trials | Cochrane. Available from: https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-23#section-23-3-4. [Cited 2026 May 18]."},{"key":"5016_CR26","unstructured":"Chapter 13. Assessing risk of bias due to missing evidence in a meta-analysis | Cochrane. Available from: https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-13.\u00a0[Cited 2026 May 19]."},{"issue":"7109","key":"5016_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/BMJ.315.7109","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334. https:\/\/doi.org\/10.1136\/BMJ.315.7109. .629 PubMed PMID: 9310563.","journal-title":"BMJ"},{"issue":"20","key":"5016_CR28","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1002\/sim.2380","volume":"25","author":"RM Harbord","year":"2006","unstructured":"Harbord RM, Egger M, Sterne JAC. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25(20):3443\u201357. https:\/\/doi.org\/10.1002\/SIM.2380. PubMed PMID: 16345038.","journal-title":"Stat Med"},{"key":"5016_CR29","unstructured":"Operating characteristics of. a rank correlation test for publication bias - PubMed. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/7786990\/. [Cited 2026 May 19]."},{"issue":"2","key":"5016_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","volume":"56","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455\u201363. https:\/\/doi.org\/10.1111\/J.0006-341X.2000.00455.X.\u00a0PubMed PMID: 10877304.","journal-title":"Biometrics"},{"issue":"7414","key":"5016_CR31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/BMJ.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/BMJ.327.7414.557 . PubMed PMID: 12958120.","journal-title":"BMJ"},{"issue":"3","key":"5016_CR32","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/jrsm.1313","volume":"10","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Akl EA, Sch\u00fcnemann HJ. Using systematic reviews in guideline development: The GRADE approach. Res Synth Methods. 2019;10(3):312\u201329. https:\/\/doi.org\/10.1002\/JRSM.1313. PubMed PMID: 30006970.","journal-title":"Res Synth Methods"},{"issue":"1","key":"5016_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3171\/jns.2005.103.1.0009","volume":"103","author":"P Vajkoczy","year":"2005","unstructured":"Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg. 2005;103(1):9\u201317. https:\/\/doi.org\/10.3171\/JNS.2005.103.1.0009.\u00a0PubMed PMID: 16121967.","journal-title":"J Neurosurg"},{"issue":"11","key":"5016_CR34","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1161\/STROKEAHA.108","volume":"39","author":"RL MacDonald","year":"2008","unstructured":"MacDonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008;39(11):3015\u201321. https:\/\/doi.org\/10.1161\/STROKEAHA.108.519942. PubMed PMID: 18688013.","journal-title":"Stroke"},{"issue":"6","key":"5016_CR35","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/STROKEAHA.111.648980","volume":"43","author":"RL MacDonald","year":"2012","unstructured":"MacDonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke. 2012;43(6):1463\u20139. https:\/\/doi.org\/10.1161\/STROKEAHA.111.648980 . PubMed PMID: 22403047.","journal-title":"Stroke"},{"issue":"1\u20132","key":"5016_CR36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000475824","volume":"44","author":"M Fujimura","year":"2017","unstructured":"Fujimura M, Joo JY, Kim JS, Hatta M, Yokoyama Y, Tominaga T. Preventive Effect of Clazosentan against Cerebral Vasospasm after Clipping Surgery for Aneurysmal Subarachnoid Hemorrhage in Japanese and Korean Patients. Cerebrovasc Dis. 2017;44(1\u20132):59\u201367. https:\/\/doi.org\/10.1159\/000475824.\u00a0PubMed PMID: 28463833.","journal-title":"Cerebrovasc Dis"},{"issue":"1","key":"5016_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10143-024-02345-9","volume":"47","author":"T Mochizuki","year":"2024","unstructured":"Mochizuki T, Ryu B, Shima S, Kamijyo E, Ito K, Ando T, et al. Comparison of efficacy between clazosentan and fasudil hydrochloride-based management of vasospasm after subarachnoid hemorrhage focusing on older and WFNS grade V patients: a single-center experience in Japan. Neurosurgical Rev 2024. 2024;47(1):1. https:\/\/doi.org\/10.1007\/s10143-024-02345-9 . PubMed PMID: 38472507.","journal-title":"Neurosurgical Rev 2024"},{"key":"5016_CR38","doi-asserted-by":"publisher","unstructured":"Okumura E, Nakaya K, Otsuka K, Jimbo H. Treatment Outcomes of Clazosentan Use During the Perioperative Period for Subarachnoid Hemorrhage. Cureus. 2025;17(2). https:\/\/doi.org\/10.7759\/CUREUS.79497.\u00a0PubMed PMID: 40135022.","DOI":"10.7759\/CUREUS.79497"},{"key":"5016_CR39","doi-asserted-by":"publisher","unstructured":"Mayer SA, Bruder N, Citerio G, Defreyne L, Dubois C, Gupta R, et al. REACT: a randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2024;1\u201312. https:\/\/doi.org\/10.3171\/2024.4.JNS232191. PubMed PMID: 39126720.","DOI":"10.3171\/2024.4.JNS232191"},{"key":"5016_CR40","doi-asserted-by":"publisher","unstructured":"Maeda T, Okawara M, Osakabe M, Yamaguchi H, Maeda T, Kurita H. Initial real-world experience of clazosentan for subarachnoid hemorrhage in Japan. World Neurosurg X. 2023;21. https:\/\/doi.org\/10.1016\/J.WNSX.2023.100253.\u00a0PubMed PMID: 38090191.","DOI":"10.1016\/J.WNSX.2023.100253"},{"key":"5016_CR41","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-3-7091","volume":"115","author":"N Etminan","year":"2013","unstructured":"Etminan N, Vergouwen MDI, Macdonald RL. Angiographic Vasospasm Versus Cerebral Infarction as Outcome Measures After Aneurysmal Subarachnoid Hemorrhage. Acta Neurochir Suppl (Wien). 2013;115:33\u201340. https:\/\/doi.org\/10.1007\/978-3-7091-1192-5_8. PubMed PMID: 22890640.","journal-title":"Acta Neurochir Suppl (Wien)"},{"key":"5016_CR42","doi-asserted-by":"publisher","unstructured":"Caner B, Hou J, Altay O, Fuj M, Zhang JH. Transition of research focus from vasospasm to early brain injury after subarachnoid hemorrhage. J Neurochem. 2012;123(SUPPL. 2):12\u201321. https:\/\/doi.org\/10.1111\/j.1471-4159.2012.07939x. PubMed PMID: 23050638.","DOI":"10.1111\/j.1471-4159.2012.07939x"},{"issue":"12","key":"5016_CR43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11883-017-0690","volume":"19","author":"JR Geraghty","year":"2017","unstructured":"Geraghty JR, Testai FD. Delayed Cerebral Ischemia after Subarachnoid Hemorrhage: Beyond Vasospasm and Towards a Multifactorial Pathophysiology. Curr Atheroscler Rep. 2017;19(12):50. https:\/\/doi.org\/10.1007\/s11883-017-0690-x. PubMed PMID: 29063300.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"5016_CR44","doi-asserted-by":"publisher","first-page":"628597","DOI":"10.1155\/2014\/628597","volume":"2014","author":"G Cossu","year":"2014","unstructured":"Cossu G, Messerer M, Oddo M, Daniel RT. To Look Beyond Vasospasm in Aneurysmal Subarachnoid Haemorrhage. Biomed Res Int. 2014;2014(1):628597. https:\/\/doi.org\/10.1155\/2014\/628597.","journal-title":"Biomed Res Int"},{"key":"5016_CR45","doi-asserted-by":"crossref","unstructured":"Endothelin receptor antagonists for subarachnoid hemorrhage - Guo. J\u2009\u2013\u20092012 | Cochrane Library [Internet]. [cited 2026 Mar 1]. Available from: https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD008354.pub2\/full","DOI":"10.1002\/14651858.CD008354.pub2"},{"issue":"10","key":"5016_CR46","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1161\/STROKEAHA.109.560243","volume":"40","author":"A Kramer","year":"2009","unstructured":"Kramer A, Fletcher J. Do endothelin-receptor antagonists prevent delayed neurological deficits and poor outcomes after aneurysmal subarachnoid hemorrhage? A meta-analysis. Stroke. 2009;40(10):3403\u20136. https:\/\/doi.org\/10.1161\/STROKEAHA.109.560243 . PubMed PMID: 19679843.","journal-title":"Stroke"},{"issue":"5","key":"5016_CR47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/cc11686","volume":"16","author":"J Ma","year":"2012","unstructured":"Ma J, Huang S, Ma L, Liu Y, Li H, You C. Endothelin-receptor antagonists for aneurysmal subarachnoid hemorrhage: an updated meta-analysis of randomized controlled trials. Crit Care 2012. 2012;16(5):5. https:\/\/doi.org\/10.1186\/cc11686.","journal-title":"Crit Care 2012"},{"issue":"6","key":"5016_CR48","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1227\/neu.0000000000002601","volume":"93","author":"JPM Pontes","year":"2023","unstructured":"Pontes JPM, Santos MDC, Gibram FC, Rodrigues NMV, Cavalcante-Neto JF, Barros ADM, et al. Efficacy and Safety of Clazosentan After Aneurysmal Subarachnoid Hemorrhage: An Updated Meta-Analysis. Neurosurgery. 2023;93(6):1208\u201319. https:\/\/doi.org\/10.1227\/neu.0000000000002601 . PubMed PMID: 37462365.","journal-title":"Neurosurgery"},{"issue":"4","key":"5016_CR49","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/FJC.0b013e3182a3718","volume":"62","author":"J Shi","year":"2013","unstructured":"Shi J, Wei L. Rho kinases in cardiovascular physiology and pathophysiology: The effect of fasudil. J Cardiovasc Pharmacol. 2013;62(4):341\u201354. https:\/\/doi.org\/10.1097\/FJC.0b013e3182a3718f. PubMed PMID: 23921309.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"5016_CR50","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.brainresbull.2009.08.021","volume":"81","author":"Sichi Satoh","year":"2010","unstructured":"Satoh Sichi, Hitomi A, Ikegaki I, Kawasaki K, Nakazono O, Iwasaki M, et al. Amelioration of endothelial damage\/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage. Brain Res Bull. 2010;81(1):191\u20135. https:\/\/doi.org\/10.1016\/j.brainresbull.2009.08.021.\u00a0PubMed PMID: 19723568.","journal-title":"Brain Res Bull"},{"key":"5016_CR51","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/978-3-7091-0356","volume":"110","author":"J Beck","year":"2011","unstructured":"Beck J, Raabe A, Clazosentan. Prevention of Cerebral Vasospasm and the Potential to Overcome Infarction. Acta Neurochir Suppl (Wien). 2011;110:147\u201350. https:\/\/doi.org\/10.1007\/978-3-7091-0356-2_26. PubMed PMID: 21125461.","journal-title":"Acta Neurochir Suppl (Wien)"},{"key":"5016_CR52","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/978-3-319","volume":"120","author":"R Dhar","year":"2015","unstructured":"Dhar R, Diringer MN. Relationship Between Angiographic Vasospasm, Cerebral Blood Flow, and Cerebral Infarction After Subarachnoid Hemorrhage. Acta Neurochir Suppl (Wien). 2015;120:161\u20135. https:\/\/doi.org\/10.1007\/978-3-319-04981-6_27. PubMed PMID: 25366617.","journal-title":"Acta Neurochir Suppl (Wien)"},{"issue":"10","key":"5016_CR53","doi-asserted-by":"publisher","first-page":"e47778","DOI":"10.1371\/journal.pone.0047778","volume":"7","author":"X Wang","year":"2012","unstructured":"Wang X, Li YM, Li WQ, Huang CG, Lu YC, Hou LJ. Effect of Clazosentan in Patients with Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE. 2012;7(10):e47778. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0047778.\u00a0PubMed PMID: 23082215.","journal-title":"PLoS ONE"},{"key":"5016_CR54","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-3-7091-1192","volume":"115","author":"RL Macdonald","year":"2013","unstructured":"Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Randomised Trial of Clazosentan, an Endothelin Receptor Antagonist, in Patients with Aneurysmal Subarachnoid Hemorrhage Undergoing Surgical Clipping (CONSCIOUS-2). Acta Neurochir Suppl (Wien). 2013;115:27\u201331. https:\/\/doi.org\/10.1007\/978-3-7091-1192-5_7. PubMed PMID: 22890639.","journal-title":"Acta Neurochir Suppl (Wien)"},{"issue":"5","key":"5016_CR55","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.hest.2025.02.003","volume":"6","author":"K Mitani","year":"2025","unstructured":"Mitani K, Miyata T, Shiraishi W, Abekura Y, Agawa Y, Ogawa T, et al. Perioperative sodium overload is associated with the occurrence of pulmonary complications related to clazosentan in patients with subarachnoid hemorrhage followed by obliterative management for ruptured aneurysm: A retrospective observational study. Brain Hemorrhages. 2025;6(5):227\u201336. https:\/\/doi.org\/10.1016\/j.hest.2025.02.003.","journal-title":"Brain Hemorrhages"},{"key":"5016_CR56","doi-asserted-by":"publisher","unstructured":"Kinoshita H, Kato K, Yamazaki Y, Hashiba E, Hirota K, Kinoshita H, et al. Successful Fluid Management in Respiratory Failure due to Clazosentan Following a Cerebral Aneurysm Clipping: A Case Report. Cureus. 2024;16(2). https:\/\/doi.org\/10.7759\/cureus.54850.","DOI":"10.7759\/cureus.54850"},{"key":"5016_CR57","doi-asserted-by":"publisher","unstructured":"Macdonald RL, Higashida R, Keller E, Mayer SA, Molyneux AJ, Raabe A, et al. Abstract 43: Effect of Clazosentan on Clinical Outcome After Aneurysmal Subarachnoid Hemorrhage and Endovascular Coiling: Results of the CONSCIOUS-3 Study. Stroke. 2012;43(suppl1). https:\/\/doi.org\/10.1161\/str.43.suppl_1.a43.","DOI":"10.1161\/str.43.suppl_1.a43"},{"issue":"6674","key":"5016_CR58","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.wneu.2018.10.213","volume":"123","author":"SS Cho","year":"2019","unstructured":"Cho SS, Kim SE, Kim HC, Kim WJ, Jeon JP. Clazosentan for Aneurysmal Subarachnoid Hemorrhage: An Updated Meta-Analysis with Trial Sequential Analysis. World Neurosurg. 2019;123(6674):418\u2013e4243. https:\/\/doi.org\/10.1016\/j.wneu.2018.10.213 . PubMed PMID: 30508597.","journal-title":"World Neurosurg"},{"key":"5016_CR59","doi-asserted-by":"publisher","first-page":"e378","DOI":"10.1016\/j.wneu.2023.01.032","volume":"172","author":"P Hu","year":"2023","unstructured":"Hu P, Yan T, Li Y, Guo G, Gao X, Su Z, et al. Effect of Surgical Clipping versus Endovascular Coiling on the Incidence of Delayed Cerebral Ischemia in Patients with Aneurysmal Subarachnoid Hemorrhage: A Multicenter Observational Cohort Study with Propensity Score Matching. World Neurosurg. 2023;172:e378\u201388. https:\/\/doi.org\/10.1016\/J.WNEU.2023.01.032 PubMed PMID: 36657714.","journal-title":"World Neurosurg"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-05016-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05016-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05016-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:53:40Z","timestamp":1784195620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-05016-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5016"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-05016-y","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research did not include human subjects and therefore did not require ethical approval.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study does not contain any personal data that would require consent for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"464"}}